Skip to main content
Environmental Health and Preventive Medicine logoLink to Environmental Health and Preventive Medicine
. 2006 Sep;11(5):256–263. doi: 10.1007/BF02898015

Breakdown of mucosal immunity in gut by 2,3,7,8-tetraclorodibenzo-p-dioxin (TCDD)

Hirokazu Kinoshita 1,2,, Jun Abe 1, Kenji Akadegawa 3, Hideaki Yurino 1, Tetsuya Uchida 4, Shigaku Ikeda 2, Kouji Matsushima 1, Sho Ishikawa 1,
PMCID: PMC2723348  PMID: 21432354

Abstract

Objectives

Mucosal immunity plays a pivotal role for body defense against infection and allergy. The aim of this study was to clarify the effects of 2,3,7,8-tetraclorodibenzo-p-dioxin (TCDD) on mucosal immunity in the gut.

Methods

Fecal IgA level and oral tolerance induction were examined in TCDD-treated mice. Flow cytometric and histological analyses were also performed.

Results

Single oral administration of low dose 2,3,7,8-TCDD resulted in a marked decrease in IgA secretion in the gut without any effects on the cellular components of gut-associated lymphoid tissues (GALT) including Peyer’s patches (PPs) and mesenteric lymph nodes (LNs). Decressed IgA secretion by TCDD was not observed in aryl hydrocarbon receptor (AhR)-deficient mice. Flow cytometric analysis revealed that IgA B cells in PPs and the mesenteric LNs remained unchanged in the TCDD-treated mice. An immunofluorescence study also demonstrated that a significant number of cytoplasmic IgA cells were present in the lamina propria of the gut in the TCDD-treated mice. Furthermore, oral tolerance induction by ovalbumin (OVA) was impaired in the TCDD-treated mice and OVA-specific T cell proliferation occurred in the peripheral lymphoid tissues including the spleen and LNs.

Conclusions

These results suggest that a relatively low dose of TCDD impairs mucosal immunity in the gut and induces systemic sensitization by oral antigens.

Key words: TCDD, mucosal immunity, IgA, oral tolerance, allergy

Abbreviations

OVA

ovalbumin

PPs

Peyer’s patches

LNs

lymph nodes

CTL

cytotoxic T lymphocytes

BWFI

(New Zealand Black × New Zealnad White) FI hybrid

SLE

systemic lupus erythematosus

HRP

horse radish peroxidase

FITC

fluorescein isothiocyanate

PE

phycoerythrin

APC

allophycocyanate

CFA

complete Freund’s adjuvant

BSA

bovine serum albumin

KLH

keyhole limpet hemocyanin

TGF

transforming growth factor

GVH

graft versus host reaction

References

  • (1).Holsapple MP, Snyder NK, Wood SC, Morris DL. A review of 2,3,7,8-tetraclorodibenzo-p-dioxin-induced changes in immuno-competence. Update. Toxicology. 1991;69:219–255. [DOI] [PubMed]
  • (2).Pohjanvirta R, Tuomisto J. Short-term toxicity of 2,3,7,8-tetraclorodibenzo-p-dioxin in laboratory animals: effects, mechanisms, and animal model. Pharmacol Rev. 1994;46:483–459. [PubMed]
  • (3).Kerkvliet NI. Immunological effects of chlorinated dibenzo-p-dioxins. Environ Health Perspect. 1995;103:47–53 [DOI] [PMC free article] [PubMed]
  • (4).Kerkvliet NI. Recent advances in understanding the mechanisms of TCDD immunotoxicity. Int Immunopharmacol. 2002; 2:277–291. [DOI] [PubMed]
  • (5).Negishi T, Kato Y, Ooneda O, Mimura J, Takada T, Mochizuki H, et al. Effects of aryl hydrocarbon receptor signaling on the modulation of Th1/Th2 balance. J Immunol. 2005;175:7348–7356. [DOI] [PubMed]
  • (6).Leubke RW, Copeland CB, Andrews DL. Effects of aging on resistance toTrichinella spiralis infection in rodents exposed to 2,3,7,8-tetraclorodibenzo-p-dioxin. Toxicology. 1996;136:15–26. [DOI] [PubMed]
  • (7).Warren TK, Mitchel KA, Lawrence BP. Exposure to 2,3,7,8-tetraclorodibenzo-p-dioxin (TCDD) suppresses the humoral and cell-mediated immune responses to influenza A virus without affecting cytolytic activity in the lung. Toxicol Sci. 2000;56:114–123. [DOI] [PubMed]
  • (8).Nohara K, Izumi H, Tamura S, Nagata R, Tohyama C. Effect of low-dose 2,3,7,8-tetraclorodibenzo-p-dioxin (TCDD) on influenza A virus-induced mortality in mice. Toxicology. 2002;170:131–138. [DOI] [PubMed]
  • (9).Metecky J, Moro I, Underdown BJ. In: Ogara P editor. Mucosal Immunology. San Diego: Academic Press; 1993. p. 133–152.
  • (10).Strobel S, Mowat A. Immune responses to dietary antigens: oral to lerance. Immuol Today. 1998;19:173–181. [DOI] [PubMed]
  • (11).Faria AMC, Weiner HL. Oral tolerance: mechanisms and therapeutic applications. Adv Immunol. 1999;73:153–161. [DOI] [PubMed]
  • (12).Ishikawa S, Sato T, Abe M, Nagai S, Onai N, Yoneyama H, et al. Aberrant high expression of B lymphocyte chemokine (BLC/CXCL13) in the development of murine lupus and preferential chemotaxis of B1 cells towards BLC. J Exp Med. 2001;193:1393–1402. [DOI] [PMC free article] [PubMed]
  • (13).Akadegawa K, Ishikawa S, Sato T, Suzuki J, Yurino H, Kitabatake M, et al. Breakdown of mucosal immunity in the gut and resultant systemic sensitization by oral antigens in a murine model for SLE. J Immunol. 2005;174:5499–5506. [DOI] [PubMed]
  • (14).von Mutius E, Fritzsch C, Weiland SK, Roll G, Magnussen H. Prevalence of asthma and allergic disorders among children in united Germany: a descriptive comparison. Br Med J. 1992;305:1395–1399. [DOI] [PMC free article] [PubMed]
  • (15).Bruce IN, Harland RW, McBride NA, MacMahon J. Trends in the prevalence of asthma and dyspnoea in first year university students, 1972–89. Quart J Med. 1993;86:425–430. [PubMed]
  • (16).Schultz-Larsen F. The epidemiology of atopic dermatitis. Monogr Allergy. 1993;31:9–328. [PubMed]
  • (17).Wichman HE. Possible explanation for the different trends of asthma and allergy in east and West Germany. Clin Exp Allergy. 1996;26:621–624. [DOI] [PubMed]
  • (18).Hopkin JM. Mechanisms of enhanced prevalence of asthma and atopy in developing countries. Curr Opin Immunol. 1997;9:788–792. [DOI] [PubMed]
  • (19).Schmidt JV, Su GH-T, Reddy JK, Simon MC. Characterization of a murine AhR null allele: Involvement of the Ah receptor in hepatic growth and development. Proc Natl Acad Sci USA. 1996;93:6731–6735. [DOI] [PMC free article] [PubMed]
  • (20).Benedict JC, Lin T-M, Loeffler IK, Peterson RE, Flaws JA. Physiological role of the Aryl hydrocarbon receptor in mouse ovary development. Toxicol Sci. 2000;56:382–388. [DOI] [PubMed]
  • (21).Anderson P, Ridderstad A, McGuire J, Petterson S, Poellinger L, Hanberg A. A constitutively active aryl hydrocarbon receptor causes loss of peritoneal B1 cells. Biochem Biophys Res Commun. 2003;302:336–341. [DOI] [PubMed]
  • (22).Hardy RR, Hayakawa K. Development and physiology of Ly-1 B and its human homolog, Leu-1 B. Immunol Rev. 1986;93:53–80. [DOI] [PubMed]
  • (23).Kroese FGM, Ammerlaan WA, Kantor AB. Many of the IgA producing plasma cells in murine gut are derived from self-replenishing precursors in the peritoneal cavity. Int Immunol. 1989;1:75–84. [DOI] [PubMed]
  • (24).MacPherson AJ, Gatto D, Sainsbury D, Harriman GR, Hengartner H, Zinkernagel RM. A primitive T cell-independent mechanism of intestinal mucosal IgA responses to commensal bacteria. Science. 2000;288:2222–2226. [DOI] [PubMed]
  • (25).Mowat AM. Anatomical basis of tolerance and immunity to intestinal antigens. Nature Rev Immunol. 2003;3:331–341. [DOI] [PubMed]
  • (26).Santos LMB, Al-Sabbagh A, London A, Weiner HL. Oral tolerance to myelin basic protein induces TGF-β secreting regulatory T cells in Peyer’s patches of SJL mice. Cell Immunol. 1994;157:439–444. [DOI] [PubMed]
  • (27).Tsuji N, Mizumachi K, Kurisaki K. Interleukin-10-secreting Peyer’s patches are responsible for active suppression in low-dose oral to lerance. Immunology. 2001;103:458–463. [DOI] [PMC free article] [PubMed]
  • (28).Spahn TW, Fontana A, Faria AMC, Slavin AJ, Eugster HP, Zhang X, et al. Induction of oral tolerance to cellular immune responses in the absence of Peyer’s patches. Eur J Immunol. 2001;31:1278–1283. [DOI] [PubMed]
  • (29).Spahn TW, Weiner HL, Renner PD, Lugering N, Fontana A, Domschke W, et al. Mesenteric lymph nodes are critical for the induction of high-dose tolerance in the absence of Peyer’s patches. Eur J Immunol. 2002;32:1109–1114. [DOI] [PubMed]
  • (30).Suh ED, Vistica BP, Chan C-C, Raber JM, Gery I, Nussenbiatt RB. Splenectomy abrogates the induction of oral tolerance in experimental autoimmune uveitis. Curr Eye Res. 1993;12:833–838. [DOI] [PubMed]
  • (31).Yoshida H, Hachimura S, Hirahara K, Hisatsune T, Nishijima K, Shiraishi A, et al. Induction of oral tolerance in splenocyte-reconstituted SCID mice. Clin Immunol Immunopathol. 1998;87:282–291. [DOI] [PubMed]
  • (32).Vinney JL, Mowat AM, O’Malley JM, Williamson E, Fanger NA. Expanding dendritic cells in vivo enhances the induction of oral tolerance. J Immunol. 1998;160:5815–5820. [PubMed]
  • (33).Huag FP, Platt N, Wykes M, Major JR, Powell TJ, Jenkins CD, et al. A discrete subpopulation of dendritic cells transports apoptotic intestinal epithelial cells to T cell areas of mesenteric lymph nodes. J Exp Med. 2000;191:435–440. [DOI] [PMC free article] [PubMed]
  • (34).Chirdo FG, Millington OR, Beacock-Scharp H, Mowat AM. Immunomodulatory dendritic cells in intestinal lamina propria. Eur J Immunol. 2000;35:1831–1840. [DOI] [PubMed]
  • (35).Funatake CJ, Marshal NB, Stephan LB, Mourich DV, Kerkvliet NI. Activation of the aryl hydrocarbon receptor by 2,3,7,8-tetrachlorodibenzo-p-dioxin generates a population of CD4+CD25+ cells with characteristics of regulatory T cells. J Immunol. 2005;175:4184–4188. [DOI] [PubMed]

Articles from Environmental Health and Preventive Medicine are provided here courtesy of The Japanese Society for Hygiene

RESOURCES